| Literature DB >> 31519066 |
Vivian Lee1,2, Michael D Gober1, Hasan Bashir1,2, Conor O'Day1, Ian A Blair3, Clementina Mesaros3, Liwei Weng3, Andrew Huang1, Aaron Chen1, Rachel Tang1, Vince Anagnos1, JiLon Li1, Sophie Roling1, Emilija Sagaityte1, Andrew Wang1, Chenyan Lin2, Christopher Yeh1, Cem Atillasoy1, Christine Marshall1, Tzvete Dentchev1, Todd Ridky1, John T Seykora1.
Abstract
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and is associated with cumulative UV exposure. Studies have shown that prolonged voriconazole use promotes cSCC formation; however, the biological mechanisms responsible for the increased incidence remain unclear. Here, we show that voriconazole directly increases oxidative stress in human keratinocytes and promotes UV-induced DNA damage as determined by comet assay, 8-oxoguanine immunofluorescence and mass spectrometry. Voriconazole treatment of human keratinocytes potentiates UV-induced apoptosis and activation of the p38 MAP kinase and 53BP1 UV stress response pathways. The p38 MAP kinase activation promoted by voriconazole exposure can be mitigated by pretreating keratinocytes with N-acetylcysteine. Voriconazole increases oxidative stress in keratinocytes by directly inhibiting catalase leading to lower intracellular NADPH levels and the triazole moieties in voriconazole are critical for inhibiting catalase. Furthermore, voriconazole is shown to promote UV-induced dysplasia in an in vivo model. Together, these data demonstrate that voriconazole potentiates oxidative stress in UV-irradiated keratinocytes through catalase inhibition. Use of antioxidants may mitigate the pro-oncogenic effects of voriconazole.Entities:
Keywords: Voriconazole; oxidative stress; squamous cell carcinoma; triazole antifungal agents
Mesh:
Substances:
Year: 2019 PMID: 31519066 PMCID: PMC7401379 DOI: 10.1111/exd.14038
Source DB: PubMed Journal: Exp Dermatol ISSN: 0906-6705 Impact factor: 3.960